These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 17975472

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Molecular mechanisms of increased intrahepatic resistance in portal hypertension.
    Shah V.
    J Clin Gastroenterol; 2007; 41 Suppl 3():S259-61. PubMed ID: 17975474
    [Abstract] [Full Text] [Related]

  • 3. Hemodynamics in the isolated cirrhotic liver.
    Zipprich A.
    J Clin Gastroenterol; 2007; 41 Suppl 3():S254-8. PubMed ID: 17975473
    [Abstract] [Full Text] [Related]

  • 4. Pathophysiology of portal hypertension.
    Bosch J, Pizcueta P, Feu F, Fernández M, García-Pagán JC.
    Gastroenterol Clin North Am; 1992 Mar; 21(1):1-14. PubMed ID: 1568769
    [Abstract] [Full Text] [Related]

  • 5. Splanchnic and systemic vasodilatation: the patient.
    Tsai MH.
    J Clin Gastroenterol; 2007 Mar; 41 Suppl 3():S266-71. PubMed ID: 17975476
    [Abstract] [Full Text] [Related]

  • 6. [Morphofunctional rearrangement of the hepatic vasculature in the pathogenesis of portal hypertension in liver cirrhosis].
    Garbuzenko DV.
    Ter Arkh; 2014 Mar; 86(2):90-5. PubMed ID: 24772515
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension.
    Iwakiri Y.
    Liver Int; 2012 Feb; 32(2):199-213. PubMed ID: 21745318
    [Abstract] [Full Text] [Related]

  • 12. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension.
    Iwakiri Y.
    J Clin Gastroenterol; 2007 Feb; 41 Suppl 3():S288-94. PubMed ID: 17975478
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?
    Thabut D, Shah V.
    J Hepatol; 2010 Nov; 53(5):976-80. PubMed ID: 20800926
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension.
    Hernández-Guerra M, García-Pagán JC, Turnes J, Bellot P, Deulofeu R, Abraldes JG, Bosch J.
    Hepatology; 2006 Mar; 43(3):485-91. PubMed ID: 16496307
    [Abstract] [Full Text] [Related]

  • 18. Pathophysiology of portal hypertension.
    Iwakiri Y.
    Clin Liver Dis; 2014 May; 18(2):281-91. PubMed ID: 24679494
    [Abstract] [Full Text] [Related]

  • 19. Pathophysiology and a Rational Basis of Therapy.
    Gracia-Sancho J, Maeso-Díaz R, Bosch J.
    Dig Dis; 2015 May; 33(4):508-14. PubMed ID: 26159267
    [Abstract] [Full Text] [Related]

  • 20. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis.
    Bolognesi M, Di Pascoli M, Verardo A, Gatta A.
    World J Gastroenterol; 2014 Mar 14; 20(10):2555-63. PubMed ID: 24627591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.